Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE NALOXONE HYDROCHLORIDE versus VIVITROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE NALOXONE HYDROCHLORIDE versus VIVITROL.
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE vs VIVITROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.
Naltrexone, as the active moiety of VIVITROL, is a competitive antagonist at opioid receptors (mu, kappa, and delta), blocking the euphoric effects of alcohol and opioids. It also modulates the hypothalamic-pituitary-adrenal axis and dopamine pathways implicated in alcohol craving.
Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.
380 mg intramuscularly every 4 weeks, alternating gluteal injections.
None Documented
None Documented
Buprenorphine: terminal half-life 24-60 hours (mean ~37 h) due to slow dissociation from opioid receptors; clinically relevant for once-daily or alternate-day dosing. Naloxone: terminal half-life 1-2 hours; rapid elimination limits oral systemic availability.
Naltrexone terminal half-life: 4-13 hours (mean 9.7 h). Active metabolite 6-β-naltrexol: 10-15 hours. Clinically, naltrexone concentrations are sustained for ~30 days after IM injection.
Buprenorphine: primarily fecal (69-70%) via biliary excretion; renal (10-30%) as unchanged drug and metabolites. Naloxone: extensively metabolized in liver, primarily conjugated; renal excretion of metabolites (70%), minimal unchanged (<1%).
Naltrexol (6-β-naltrexol) and naltrexone: primarily renal (60-70% as metabolites, <5% as unchanged drug); biliary/fecal (minor route, <10%).
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist